Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LSTA Stock Forecast 2025-2026
$1.97
Current Price
$17.38M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to LSTA Price Targets
+661.4%
To High Target of $15.00
+661.4%
To Median Target of $15.00
+356.9%
To Low Target of $9.00
LSTA Price Momentum
-4.4%
1 Week Change
-4.4%
1 Month Change
-27.3%
1 Year Change
-33.9%
Year-to-Date Change
-53.1%
From 52W High of $4.20
+8.8%
From 52W Low of $1.81
📊 TOP ANALYST CALLS
Did LSTA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Lisata Therapeutics is one of their latest high-conviction picks.
Latest LSTA Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, LSTA has a bullish consensus with a median price target of $15.00 (ranging from $9.00 to $15.00). The overall analyst rating is N/A (N/A/10). Currently trading at $1.97, the median forecast implies a 661.4% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 661.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LSTA Analyst Ratings
3
Buy
0
Hold
0
Sell
LSTA Price Target Range
Low
$9.00
Average
$15.00
High
$15.00
Current: $1.97
Latest LSTA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LSTA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 21, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $15.00 |
| Jul 15, 2025 | Brookline Capital | Kemp Dolliver | Buy | Maintains | $32.00 |
| Dec 11, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $15.00 |
| Nov 21, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $15.00 |
| Sep 18, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $15.00 |
| Aug 13, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $15.00 |
| Jul 19, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $15.00 |
| Jul 10, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $15.00 |
| Jun 14, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $15.00 |
| May 21, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $15.00 |
| Apr 26, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $15.00 |
| Apr 25, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $15.00 |
| Mar 1, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $15.00 |
| Jan 4, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $15.00 |
| Aug 15, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $15.00 |
| May 25, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $15.00 |
| Mar 31, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $15.00 |
| Oct 19, 2022 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $15.00 |
Lisata Therapeutics Inc. (LSTA) Competitors
The following stocks are similar to Lisata Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Lisata Therapeutics Inc. (LSTA) Financial Data
Lisata Therapeutics Inc. has a market capitalization of $17.38M with a P/E ratio of -0.8x. The company generates $1.07M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -100.0% quarter-over-quarter, while maintaining an operating margin of -1,876.5% and return on equity of -72.2%.
Valuation Metrics
Market Cap
$17.38M
Enterprise Value
$-1,875,156
P/E Ratio
-0.8x
PEG Ratio
0.0x
Price/Sales
16.2x
Growth & Margins
Revenue Growth (YoY)
-100.0%
Gross Margin
N/A
Operating Margin
-1,876.5%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+109.3%
Current Ratio
4.7x
Debt/Equity
0.0x
ROE
-72.2%
ROA
-41.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Lisata Therapeutics Inc. (LSTA) Business Model
About Lisata Therapeutics Inc.
What They Do
Develops advanced therapies for serious diseases.
Business Model
Lisata Therapeutics Inc. focuses on biotechnology, utilizing proprietary and collaborative research to develop innovative cell therapies targeted at cardiovascular diseases and other critical health conditions. The company's revenue is primarily generated through partnerships, research grants, and the potential commercialization of its therapeutic products.
Additional Information
Located in a dynamic biotech environment, Lisata Therapeutics is well-positioned to contribute to advancements in healthcare, particularly in cardiology and regenerative medicine, which may attract investment interest due to its potential for transformative solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
26
CEO
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.
Country
United States
IPO Year
N/A
Website
www.lisata.comLisata Therapeutics Inc. (LSTA) Latest News & Analysis
Latest News
Lisata Therapeutics receives 2025 BioTech Breakthrough Award for 'Overall BioPharma Solution of the Year'
1 month ago
Quick Summary
Lisata Therapeutics Inc (NASDAQ:LSTA) has received the "Overall BioPharma Solution of the Year" award from BioTech Breakthrough, recognizing its innovative approach in addressing advanced solid tumors.
Why It Matters
Lisata Therapeutics' award highlights its innovative approach and credibility in the biotech sector, potentially boosting investor confidence and attracting interest in its future growth prospects.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
Lisata Therapeutics (NASDAQ:LSTA) reported Q3 financial results, noting clinical progress with certepetide and new collaborations to enhance its development and discovery efforts.
Why It Matters
Lisata's Q3 results show clinical advancements for certepetide and new collaborations, indicating potential growth and innovation, which could enhance investor confidence and stock value.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
Lisata Therapeutics, Inc. (LSTA) will hold its Q3 2025 earnings call on November 6, 2025, featuring key executives discussing financial results and business updates.
Why It Matters
Lisata Therapeutics' Q3 earnings call reveals financial performance and strategic updates, vital for assessing the company's growth potential and investment viability.
Source: Seeking Alpha
Market Sentiment:
Neutral
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
1 month ago
Quick Summary
Catalent has signed a global license agreement for certepetide, partnering with GATC Health for AI drug discovery. Their cash runway extends to Q1 2027, with no debt. A conference call is scheduled for today at 4:30 p.m. ET.
Why It Matters
Certepetide's effectiveness boosts its market potential. Catalent's licensing agreement and extended cash runway enhance financial stability, signaling growth opportunities for investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year'
1 month ago
Quick Summary
Lisata Therapeutics, Inc. (Nasdaq: LSTA) has been awarded "Overall BioPharma Solution of the Year" at the BioTech Breakthrough Awards, recognizing its innovative therapies for advanced solid tumors.
Why It Matters
Lisata Therapeutics winning a prestigious award enhances its credibility and visibility in the biotech sector, potentially attracting investment and boosting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Lisata Therapeutics reports preclinical data showing certepetide's potential to enhance cancer drug delivery
1 month ago
Quick Summary
Lisata Therapeutics (NASDAQ:LSTA) announced positive preclinical results for certepetide, which may enhance antibody-drug conjugates in cancer treatment by improving tumor penetration.
Why It Matters
Lisata's positive preclinical results for certepetide could boost ADC effectiveness in cancer treatment, potentially increasing market interest and stock value for LSTA.
Source: Proactive Investors
Market Sentiment:
Positive
Frequently Asked Questions About LSTA Stock
What is Lisata Therapeutics Inc.'s (LSTA) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Lisata Therapeutics Inc. (LSTA) has a median price target of $15.00. The highest price target is $15.00 and the lowest is $9.00.
Is LSTA stock a good investment in 2026?
According to current analyst ratings, LSTA has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.97. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LSTA stock?
Wall Street analysts predict LSTA stock could reach $15.00 in the next 12 months. This represents a 661.4% increase from the current price of $1.97. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lisata Therapeutics Inc.'s business model?
Lisata Therapeutics Inc. focuses on biotechnology, utilizing proprietary and collaborative research to develop innovative cell therapies targeted at cardiovascular diseases and other critical health conditions. The company's revenue is primarily generated through partnerships, research grants, and the potential commercialization of its therapeutic products.
What is the highest forecasted price for LSTA Lisata Therapeutics Inc.?
The highest price target for LSTA is $15.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 661.4% increase from the current price of $1.97.
What is the lowest forecasted price for LSTA Lisata Therapeutics Inc.?
The lowest price target for LSTA is $9.00 from at , which represents a 356.9% increase from the current price of $1.97.
What is the overall LSTA consensus from analysts for Lisata Therapeutics Inc.?
The overall analyst consensus for LSTA is bullish. Out of 2 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $15.00.
How accurate are LSTA stock price projections?
Stock price projections, including those for Lisata Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 5:49 PM UTC